Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man

Attila Cziraki, I. Horváth, Joseph W. Rubin, Michael Theodorakis, John D. Catravas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Angiotensin converting enzyme (ACE, kininase II) is an endothelial luminal ectoenzyme expressed abundantly on the pulmonary capillary endothelium and recognized as the site for the conversion of circulating angiotensin I to II. In the present study, we have applied recently developed methodologies for assaying pulmonary capillary endothelium-bound (PCEB) ACE activity in man, to estimate the interaction of an ACE inhibitor (enalaprilat) with PCEB ACE in human subjects. Trace amounts of the specific ACE substrate, 3H-benzoyl-Phe-Ala-Pro (3H-BPAP; 40 Ci or 2 nmol), was injected as a bolus into the subclavian vein and immediately blood was withdrawn from a radial arterial catheter. Plasma concentrations of surviving substrate and product (3H-benzoyl-Phe) were estimated and BPAP utilization was calculated during a single transpulmonary passage, at baseline (T0) and at 15 min (T15) and 2 h (T120) after intravenous administration of 1.5 g/kg enalaprilat in 12 normotensive subjects. This treatment had no significant effect on mean arterial pressure (91 ± 6 vs. 84 ± 7 vs. 88 ± 6 mm Hg for T0, T15 and T120, respectively), but significantly decreased serum and PCEB ACE activities. When normalized to predrug (T0) activity levels, enalaprilat inhibited PCEB and serum ACE activities at T15 74 ± 6% and 68 ± 6%, respectively. However, 2 h after enalaprilat (T120), PCEB ACE inhibition was maintained at 66 ± 7%, whereas serum ACE inhibition was reduced to 46 ± 8% (P <.01 from PCEB ACE), suggesting a preferential PCEB ACE inhibitory effect of enalaprilat.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalGeneral Pharmacology
Volume35
Issue number4
DOIs
Publication statusPublished - 2000

Fingerprint

Vascular Endothelium
Peptidyl-Dipeptidase A
Enalaprilat
Lung
Serum
Subclavian Vein
Angiotensin I
Angiotensin-Converting Enzyme Inhibitors
Intravenous Administration
Arterial Pressure
Catheters

Keywords

  • ACE
  • ACE inhibitors
  • Enalaprilat
  • Indicator dilution
  • Pulmonary endothelium

ASJC Scopus subject areas

  • Pharmacology

Cite this

Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man. / Cziraki, Attila; Horváth, I.; Rubin, Joseph W.; Theodorakis, Michael; Catravas, John D.

In: General Pharmacology, Vol. 35, No. 4, 2000, p. 213-218.

Research output: Contribution to journalArticle

Cziraki, Attila ; Horváth, I. ; Rubin, Joseph W. ; Theodorakis, Michael ; Catravas, John D. / Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man. In: General Pharmacology. 2000 ; Vol. 35, No. 4. pp. 213-218.
@article{216d76e5e0a345ff8ea9aabe23d8cfbb,
title = "Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man",
abstract = "Angiotensin converting enzyme (ACE, kininase II) is an endothelial luminal ectoenzyme expressed abundantly on the pulmonary capillary endothelium and recognized as the site for the conversion of circulating angiotensin I to II. In the present study, we have applied recently developed methodologies for assaying pulmonary capillary endothelium-bound (PCEB) ACE activity in man, to estimate the interaction of an ACE inhibitor (enalaprilat) with PCEB ACE in human subjects. Trace amounts of the specific ACE substrate, 3H-benzoyl-Phe-Ala-Pro (3H-BPAP; 40 Ci or 2 nmol), was injected as a bolus into the subclavian vein and immediately blood was withdrawn from a radial arterial catheter. Plasma concentrations of surviving substrate and product (3H-benzoyl-Phe) were estimated and BPAP utilization was calculated during a single transpulmonary passage, at baseline (T0) and at 15 min (T15) and 2 h (T120) after intravenous administration of 1.5 g/kg enalaprilat in 12 normotensive subjects. This treatment had no significant effect on mean arterial pressure (91 ± 6 vs. 84 ± 7 vs. 88 ± 6 mm Hg for T0, T15 and T120, respectively), but significantly decreased serum and PCEB ACE activities. When normalized to predrug (T0) activity levels, enalaprilat inhibited PCEB and serum ACE activities at T15 74 ± 6{\%} and 68 ± 6{\%}, respectively. However, 2 h after enalaprilat (T120), PCEB ACE inhibition was maintained at 66 ± 7{\%}, whereas serum ACE inhibition was reduced to 46 ± 8{\%} (P <.01 from PCEB ACE), suggesting a preferential PCEB ACE inhibitory effect of enalaprilat.",
keywords = "ACE, ACE inhibitors, Enalaprilat, Indicator dilution, Pulmonary endothelium",
author = "Attila Cziraki and I. Horv{\'a}th and Rubin, {Joseph W.} and Michael Theodorakis and Catravas, {John D.}",
year = "2000",
doi = "10.1016/S0306-3623(01)00110-0",
language = "English",
volume = "35",
pages = "213--218",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man

AU - Cziraki, Attila

AU - Horváth, I.

AU - Rubin, Joseph W.

AU - Theodorakis, Michael

AU - Catravas, John D.

PY - 2000

Y1 - 2000

N2 - Angiotensin converting enzyme (ACE, kininase II) is an endothelial luminal ectoenzyme expressed abundantly on the pulmonary capillary endothelium and recognized as the site for the conversion of circulating angiotensin I to II. In the present study, we have applied recently developed methodologies for assaying pulmonary capillary endothelium-bound (PCEB) ACE activity in man, to estimate the interaction of an ACE inhibitor (enalaprilat) with PCEB ACE in human subjects. Trace amounts of the specific ACE substrate, 3H-benzoyl-Phe-Ala-Pro (3H-BPAP; 40 Ci or 2 nmol), was injected as a bolus into the subclavian vein and immediately blood was withdrawn from a radial arterial catheter. Plasma concentrations of surviving substrate and product (3H-benzoyl-Phe) were estimated and BPAP utilization was calculated during a single transpulmonary passage, at baseline (T0) and at 15 min (T15) and 2 h (T120) after intravenous administration of 1.5 g/kg enalaprilat in 12 normotensive subjects. This treatment had no significant effect on mean arterial pressure (91 ± 6 vs. 84 ± 7 vs. 88 ± 6 mm Hg for T0, T15 and T120, respectively), but significantly decreased serum and PCEB ACE activities. When normalized to predrug (T0) activity levels, enalaprilat inhibited PCEB and serum ACE activities at T15 74 ± 6% and 68 ± 6%, respectively. However, 2 h after enalaprilat (T120), PCEB ACE inhibition was maintained at 66 ± 7%, whereas serum ACE inhibition was reduced to 46 ± 8% (P <.01 from PCEB ACE), suggesting a preferential PCEB ACE inhibitory effect of enalaprilat.

AB - Angiotensin converting enzyme (ACE, kininase II) is an endothelial luminal ectoenzyme expressed abundantly on the pulmonary capillary endothelium and recognized as the site for the conversion of circulating angiotensin I to II. In the present study, we have applied recently developed methodologies for assaying pulmonary capillary endothelium-bound (PCEB) ACE activity in man, to estimate the interaction of an ACE inhibitor (enalaprilat) with PCEB ACE in human subjects. Trace amounts of the specific ACE substrate, 3H-benzoyl-Phe-Ala-Pro (3H-BPAP; 40 Ci or 2 nmol), was injected as a bolus into the subclavian vein and immediately blood was withdrawn from a radial arterial catheter. Plasma concentrations of surviving substrate and product (3H-benzoyl-Phe) were estimated and BPAP utilization was calculated during a single transpulmonary passage, at baseline (T0) and at 15 min (T15) and 2 h (T120) after intravenous administration of 1.5 g/kg enalaprilat in 12 normotensive subjects. This treatment had no significant effect on mean arterial pressure (91 ± 6 vs. 84 ± 7 vs. 88 ± 6 mm Hg for T0, T15 and T120, respectively), but significantly decreased serum and PCEB ACE activities. When normalized to predrug (T0) activity levels, enalaprilat inhibited PCEB and serum ACE activities at T15 74 ± 6% and 68 ± 6%, respectively. However, 2 h after enalaprilat (T120), PCEB ACE inhibition was maintained at 66 ± 7%, whereas serum ACE inhibition was reduced to 46 ± 8% (P <.01 from PCEB ACE), suggesting a preferential PCEB ACE inhibitory effect of enalaprilat.

KW - ACE

KW - ACE inhibitors

KW - Enalaprilat

KW - Indicator dilution

KW - Pulmonary endothelium

UR - http://www.scopus.com/inward/record.url?scp=0034580597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034580597&partnerID=8YFLogxK

U2 - 10.1016/S0306-3623(01)00110-0

DO - 10.1016/S0306-3623(01)00110-0

M3 - Article

VL - 35

SP - 213

EP - 218

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 4

ER -